Insider Selling: Prestige Consumer Healthcare (NYSE:PBH) VP Sells 346 Shares of Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) VP Jeffrey Zerillo sold 346 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $55.32, for a total value of $19,140.72. Following the completion of the transaction, the vice president owned 44,334 shares of the company’s stock, valued at approximately $2,452,556.88. The trade was a 0.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jeffrey Zerillo also recently made the following trade(s):

• On Wednesday, February 11th, Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock. The stock was sold at an average price of $65.93, for a total value of $65,930.00.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH traded down $1.55 during midday trading on Wednesday, reaching $54.20. The company’s stock had a trading volume of 519,183 shares, compared to its average volume of 461,679. The business’s fifty day simple moving average is $60.83 and its 200-day simple moving average is $62.03. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. Prestige Consumer Healthcare Inc. has a fifty-two week low of $51.24 and a fifty-two week high of $89.37. The company has a market capitalization of $2.56 billion, a P/E ratio of 14.34, a P/E/G ratio of 1.65 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The company had revenue of $283.44 million for the quarter, compared to the consensus estimate of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The firm’s revenue was down 2.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.54 EPS for the current fiscal year.

Institutional Trading of Prestige Consumer Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC grew its stake in shares of Prestige Consumer Healthcare by 11.9% during the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock worth $2,558,000 after purchasing an additional 3,200 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Prestige Consumer Healthcare by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock worth $2,535,000 after buying an additional 1,289 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Prestige Consumer Healthcare by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after acquiring an additional 120,965 shares during the last quarter. Jane Street Group LLC raised its position in shares of Prestige Consumer Healthcare by 204.0% in the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock valued at $9,010,000 after acquiring an additional 70,330 shares during the period. Finally, Geneos Wealth Management Inc. raised its position in shares of Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after acquiring an additional 269 shares during the period. Institutional investors own 99.95% of the company’s stock.

Analyst Upgrades and Downgrades

PBH has been the topic of several recent research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, April 21st. Jefferies Financial Group cut their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th. Three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and a consensus price target of $76.50.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).